Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.
Product Name : ELE-101
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Psilocin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Silver Spike Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Details : Merger also to support nationwide expansion of Eleusis’s subsidiary Andala, which manages in-network drug therapy clinics targeting the “last mile” challenge of psychedelic care delivery to address a potential $7 billion U.S. health care services o...
Product Name : ELE-Psilo
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 20, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Silver Spike Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Psilocybine,LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.
Product Name : ELE-Psilo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 03, 2020
Lead Product(s) : Psilocybine,LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable